SCHEMBL4152914

SCHEMBL4152914

COC(=O)CNCc1cccc(-c2c[c]cnc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 2/20 0.43
EPHX2 P34913 1/20 0.43
SCN8A Q9UQD0 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
PPID Q08752 1/20 0.37
KDM4C Q9H3R0 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
AURKA O14965 1/20 0.36
EGLN1 Q9GZT9 4/20 0.36
VEGFA P15692 2/20 0.36
FLT1 P17948 2/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
PDCD1 Q15116 2/20 0.36
CD274 Q9NZQ7 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPK1 P28482 1/20 0.36
VSIR Q9H7M9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666969 0.87 VSIR (0.43) PRMT6EPHX2SCN8AKDM4CPDCD1
SCHEMBL4167973 0.85 PPID (0.38) PPIDCYP11B1CYP11B2EGLN1VEGFA
SCHEMBL13778408 0.81 SCN8A (0.43) PRMT6EPHX2SCN8ACYP4F2CYP4A11
SCHEMBL3663779 0.80 FFAR1 (0.42) PRMT6EPHX2SCN8AKDM4CPDCD1
SCHEMBL3721345 0.80 CYP11B1 (0.42) PRMT6EPHX2SCN8ACYP4F2CYP4A11
SCHEMBL3724194 0.80 PRMT6 (0.66) PRMT6EPHX2SCN8AKDM4CBACE1
SCHEMBL3724516 0.80 AOC3 (0.41) PRMT6EPHX2CYP4F2CYP4A11MEN1
SCHEMBL3666546 0.79 PRMT6 (0.48) PRMT6EPHX2SCN8APDCD1CD274
SCHEMBL3664072 0.77 SCN8A (0.46) PRMT6EPHX2SCN8APDCD1CD274
SCHEMBL3730365 0.75 GRIN2D (0.47) PRMT6EPHX2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101970435-B Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG 2014-07-02 CN claimed
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 US claimed
CN-101970435-A Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG 2011-02-09 CN claimed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 PRMT6 1956/4885EPHX2 3222/4885SCN8A 1735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.